Zomig Side Effects Center

Last updated on RxList: 5/4/2022
Zomig Side Effects Center

What Is Zomig?

Zomig (zolmitriptan) is a headache medicine that narrows blood vessels around the brain used to treat migraine headaches. Zomig will only treat a headache that has already begun. Zomig will not prevent headaches or reduce the number of attacks.

What Are Side Effects of Zomig?

Common side effects of Zomig include:

  • unusual or unpleasant taste in your mouth,
  • discomfort in the nose or throat after using the nasal spray,
  • warmth/redness/tingling/numbness under the skin,
  • nausea,
  • dry mouth,
  • weakness,
  • drowsiness,
  • dizziness, or
  • pressure or heavy feeling in any part of your body.

Dosage for Zomig

The initial dose of Zomig is 2.5 mg or less. The dose can be repeated after 2 hours if symptoms persist. The maximum dose is 10 mg per day.

What Drugs, Substances, or Supplements Interact with Zomig?

Zomig may interact with other migraine headache medicines, cimetidine, or antidepressants. Tell your doctor all medications you are taking.

Zomig During Pregnancy and Breastfeeding

During pregnancy, Zomig should be used only when prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.

Additional Information

Our Zomig (zolmitriptan) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


16 Surprising Headache Triggers and Tips for Pain Relief See Slideshow
Zomig Consumer Information

3 pharmacies near 20147 have coupons for Zomig (Brand Names:Zomig for 6 Tablets)

Harris Teeter Pharmacy
Harris Teeter Pharmacy

Est. Regular Price


with free coupon

View Coupon
Walmart Pharmacy
Walmart Pharmacy

Est. Regular Price


with free coupon

View Coupon
Wegmans Food Markets Inc
Wegmans Food Markets Inc

Est. Regular Price


with free coupon

View Coupon

Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Stop using zolmitriptan and call your doctor at once if you have:

  • feeling of tightness in your jaw, neck, throat, or chest;
  • fast or pounding heartbeats, dizziness;
  • sudden and severe stomach pain and bloody diarrhea;
  • heart attack symptoms--chest pain or pressure, pain spreading to your jaw or shoulder, nausea, sweating; or
  • high levels of serotonin in the body--agitation, hallucinations, fever, fast heart rate, overactive reflexes, nausea, vomiting, diarrhea, loss of coordination, fainting.

Common side effects may include:

  • pain or tightness in your throat or chest;
  • dry mouth, upset stomach;
  • pressure or heavy feeling anywhere in your body;
  • drowsiness, feeling tired; or
  • flushing (warmth, redness, or tingly feeling).

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Zomig (Zolmitriptan)


Who suffers more frequently from migraine headaches? See Answer
Zomig Professional Information


The following adverse reactions are described elsewhere in other sections of the prescribing information:

  • Myocardial Ischemia, Myocardial Infarction, and Prinzmetal Angina [see WARNINGS AND PRECAUTIONS].
  • Arrhythmias [see WARNINGS AND PRECAUTIONS].
  • Chest and or Throat, Neck and Jaw Pain/Tightness/Pressure [see WARNINGS AND PRECAUTIONS].
  • Cerebrovascular Events [see WARNINGS AND PRECAUTIONS].
  • Other Vasospasm Reactions [see WARNINGS AND PRECAUTIONS].
  • Medication Overuse Headache [see WARNINGS AND PRECAUTIONS].
  • Serotonin Syndrome [see WARNINGS AND PRECAUTIONS].
  • Increase in Blood Pressure [see WARNINGS AND PRECAUTIONS].
  • Risks in Patients with Phenylketonuria [see WARNINGS AND PRECAUTIONS].

Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

In a long-term, open-label study where patients were allowed to treat multiple migraine attacks for up to 1 year, 8% (167 out of 2,058) withdrew from the trial because of adverse reaction.

The most common adverse reactions (≥5% and >placebo) in these trials were neck/throat/jaw pain, dizziness, paresthesia, asthenia, somnolence, warm/cold sensation, nausea, heaviness sensation, and dry mouth.

Table 1 lists the adverse reactions that occurred in ≥2% of the 2,074 patients in any one of the ZOMIG 1 mg, 2.5 mg, or 5 mg dose groups in the controlled clinical trials of ZOMIG in patients with migraines (Studies 1, 2, 3, 4, and 5) [see Clinical Studies]. Only adverse reactions that were at least 2% more frequent in a ZOMIG group compared to the placebo group are included.

Several of the adverse reactions appear dose related, notably paresthesia, sensation of heaviness or tightness in chest, neck, jaw, and throat, dizziness, somnolence and possibly asthenia and nausea.

Table 1: Adverse Reaction Incidence in Five Pooled Placebo-Controlled Migraine Clinical Trials*

1 mg
2.5 mg
5 mg
Paresthesia (all types) 2% 5% 7% 9%
Warm/cold sensation 4% 6% 5% 7%
Chest - pain/tightness/pressure and/or heaviness 1% 2% 3% 4%
Neck/throat/jaw - pain/tightness/pressure 3% 4% 7% 10%
Heaviness other than chest or neck 1% 1% 2% 5%
Other- Pressure/tightness/heaviness 0% 2% 2% 2%
DIGESTIVE 8% 11% 16% 14%
Dry mouth 2% 5% 3% 3%
Dyspepsia 1% 3% 2% 1%
Dysphagia 0% 0% 0% 2%
Nausea 4% 4% 9% 6%
NEUROLOGICAL 10% 11% 17% 21%
Dizziness 4% 6% 8% 10%
Somnolence 3% 5% 6% 8%
Vertigo 0% 0% 0% 2%
Asthenia 3% 5% 3% 9%
Sweating 1% 0% 2% 3%
* Only adverse reactions that were at least 2% more frequent in a ZOMIG group compared to the placebo group are included.

There were no differences in the incidence of adverse reactions in controlled clinical trials in the following subgroups: gender, weight, age, use of prophylactic medications, or presence of aura. There were insufficient data to assess the impact of race on the incidence of adverse reactions.

Less Common Adverse Reactions With ZOMIG Tablets

In the paragraphs that follow, the frequencies of less commonly reported adverse clinical reactions are presented. Because the reports include reactions observed in open and uncontrolled studies, the role of ZOMIG in their causation cannot be reliably determined. Furthermore, variability associated with adverse reaction reporting, the terminology used to describe adverse reactions, etc., limit the value of the quantitative frequency estimates provided. Adverse reaction frequencies were calculated as the number of patients who used ZOMIG tablets and reported a reaction divided by the total number of patients exposed to ZOMIG tablets (n=4,027). Reactions were further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: infrequent adverse reactions (those occurring in 1/100 to 1/1,000 patients) and rare adverse reactions (those occurring in less than 1/1,000 patients).

General: Infrequent were allergic reactions.

Cardiovascular: Infrequent were arrhythmias, hypertension, and syncope. Rare was tachycardia.

Neurological: Infrequent were agitation, anxiety, depression, emotional lability and insomnia; Rare were amnesia, hallucinations, and cerebral ischemia.

Skin: Infrequent were pruritus, rash, and urticaria.

Urogenital: Infrequent were polyuria, urinary frequency, and urinary urgency.

Adverse Reactions With ZOMIG-ZMT Orally Disintegrating Tablets

The adverse reaction profile seen with ZOMIG-ZMT Orally Disintegrating Tablets was similar to that seen with ZOMIG tablets.

Postmarketing Experience

The following adverse reactions were identified during post approval use of ZOMIG. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The reactions enumerated include all except those already listed in the Clinical Trials Experience section above or the Warnings and Precautions section.

Hypersensitivity Reactions

As with other 5-HT1B/ID agonists, there have been reports of anaphylaxis, anaphylactoid, and hypersensitivity reactions including angioedema in patients receiving ZOMIG. ZOMIG is contraindicated in patients with a history of hypersensitivity reaction to ZOMIG.


Ergot-Containing Drugs

Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine containing or ergot-type medications (like dihydroergotamine or methysergide) and ZOMIG within 24 hours of each other is contraindicated [see CONTRAINDICATIONS].

MAO-A Inhibitors

MAO-A inhibitors increase the systemic exposure of zolmitriptan and its active N-desmethyl metabolite. Therefore, the use of ZOMIG in patients receiving MAO-A inhibitors is contraindicated [see CONTRAINDICATIONS and CLINICAL PHARMACOLOGY].

5-HT1B/1D Agonists

Concomitant use of other 5-HT1B/1D agonists (including triptans) within 24 hours of ZOMIG treatment is contraindicated because the risk of vasospastic reactions may be additive [see CONTRAINDICATIONS].

Selective Serotonin Reuptake Inhibitors And Serotonin Norepinephrine Reuptake Inhibitors

Cases of life-threatening serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see WARNINGS AND PRECAUTIONS].


Following administration of cimetidine, the half-life and blood levels of zolmitriptan and its active N-desmethyl metabolite were approximately doubled [see CLINICAL PHARMACOLOGY]. If cimetidine and ZOMIG are used concomitantly, limit the maximum single dose of ZOMIG to 2.5 mg, not to exceed 5 mg in any 24-hour period [see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY].

Read the entire FDA prescribing information for Zomig (Zolmitriptan)

© Zomig Patient Information is supplied by Cerner Multum, Inc. and Zomig Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors